Immunodeficient Mouse and Xenograft Host Comparisons
From the most highly immunodeficient mouse available— NSG™ (005557) - to nude mice (002019), the JAX immunodeficient suite of mice are powerful xenograft models for studying solid and hematopoietic tumors, cancer stem cells, hematopoeisis, humanized mice and infectious disease.
Comparison table:
Name & Stock Number |
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (005557) |
NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (007799) |
NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ (013062) |
NOD.CB17-Prkdcscid/J (001303) |
---|---|---|---|---|
Common name | NSG™, NOD scid gamma | NRG, NOD Rag gamma | NSGS, NOD scid gamma Il3- GM-SF (NSG-SGM3) | NOD scid |
Mature B cells | Absent | Absent | Absent | Absent |
Mature T cells | Absent | Absent | Absent | Absent |
Dendritic cells | Defective | Defective | Defective | Defective |
Macrophages | Defective | Defective | Defective | Defective |
Natural killer cells | Absent | Absent | Absent | Defective |
Complement | Absent | Absent | Absent | Absent |
Leakiness | Very Low | Absent | Absent | Low |
Irradiation tolerance | Low | High | Low | Low |
Lymphoma incidence | Low | Low | Low | High (thymic lymphoma) |
Median survival | > 89 weeks | Not determined | Not determined | 36 weeks |
Benefits |
|
|
|
|
Considerations |
|
|
|
|
References |
Ishikawa et al. 2005; |
Nicolini et al. 2004; |
Shultz et al. 1995 |
Comparison table (con't):
Name & Stock Number | CBySmn.CB17-Prkdcscid/J (001803) | B6.129S7-Rag1tm1Mom/J (002216) | J:NU (007850) | NU/J (002019) |
---|---|---|---|---|
Common name | BALB scid | B6 Rag1 | Nude | Nude |
Mature B cells | Absent | Absent | Present | Present |
Mature T cells | Absent | Absent | Absent | Absent |
Dendritic cells | Present | Present | Present | Present |
Macrophages | Present | Present | Present | Present |
Natural killer cells | Present | Present | Present | Present |
Complement | Present | Present | Present | Present |
Leakiness | Low | Absent | N/A | N/A |
Irradiation tolerance | Low | High | High | High |
Lymphoma incidence | High (thymic lymphoma) | Low | Low | Low |
Median survival | Not determined | Not determined | Not determined | Not determined |
Benefits |
|
|
|
|
Considerations |
|
|
|
|
Referencess | Nonoyama et al. 1993 | Mombaerts et al. 1992 | Kelland LR. 2004 | Kelland LR. 2004 |
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (005557)
The most powerful immunodeficient model that has changed the face of oncology, stem cell and infectious disease research.
- Commonly known as “NSG™” or “NOD scid gamma” (Shultz et al. 2005)
- Severe defects in innate and adaptive immunity
- Lacks mature T, B, and functional NK cells
- Deficient in signaling of multiple cytokines (IL2, IL4, IL7, IL9, IL15 and IL21), resulting in significantly improved engraftment of human tissues, hematopoietic stem cells, and peripheral blood mononuclear cells
- Resistant to lymphoma, allowing for long-term experiments
- Capable of maintaining a human tumor microenvironment after engraftment
- Low tolerance for irradiation
NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/SzJ (007799)
- Commonly known as "NRG" or "NOD Rag gamma” (Pearson et al. 2008)
- Severe defects in innate and adaptive immunity
- Lacks mature T, B, and functional NK cells
- Engrafts human PBMC without irradiation
- Tolerant to irradiation
NOD.Cg-PrkdscidIl2rgtm1WjlTg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ/ (013062)
- Commonly known as "NSGS" or "NSG-SGM3"
- The expression of several transgenic human cytokines supports higher levels of human myeloid cell expansion
- Significant engraftment of patient-derived AML samples
- Commonly called “NOD scid” (Shultz et al. 1995)
- Lack functional T and B cells
- Thymus, lymph node, and spleen virtually devoid of lymphocytes
- NOD genetic background results in reduced NK cell activity, impaired complement pathway, and least “leakiness” of residual T and B cells of any scid strain
- Accepts allogeneic and xenogeneic grafts very efficiently and has been used successfully to transplant a variety of normal and malignant human cells and tissues, including isolates from hematopoietic cancers
- Insulitis - and diabetes-free throughout life
- Often develops thymic lymphomas by eight and a half months
- Radiation-sensitive
- Part of our unique Genetic Stability Program
CBySmn.CB17-Prkdcscid/J (001803)
- Commonly called “BALB scid”
- Deficient in mature T and B cells (Nonoyama et al. 1993)
- Innate immunity remains intact
- Normal antigen presentation, myeloid development, and NK cell functions
- Most mice are devoid of immunoglobulins
- Older mice can become "leaky," producing small numbers of mature T and B cells
B6.129S7-Rag1tm1Mom/J (002216)
- Commonly called “B6 Rag1”
- Produces no mature T or B cells (Mombaerts et al. 1992)
- Innate immunity remains intact
- Defective in V(D)J recombination and has no CD3+ or T cell receptor alpha/beta positive cells
- Thymocytes are CD4- CD8- and most are IL2R+
- Unlike scid mutants on the same genetic background, is considered “non-leaky” and is radiation-resistant
- Commonly called “Outbred Nude”
- Segregating genetic background improves hybrid vigor
- Homozygous for the nude spontaneous mutation (Foxn1nu (Pantelouris EM. 1973; Flanagan SP. 1966))
- Abnormal hair growth, making engraftment of human or mouse cancer cells, and tumor regression following treatment, easily observable
- Athymic: lack T cells and thus incapable of cell-mediated immunity, B cell development is partially defective
- Produces normal T cell precursors, and produces mature T cells with time
- Responses to thymus-dependent antigens (when detectable) are primarily IgM
- Commonly called “Inbred Nude”
- Have a uniform genetic background that can improve experimental reproducibility
- Homozygous for the nude spontaneous mutation (Foxn1nu(Pantelouris EM. 1973; Flanagan SP. 1966))
- Abnormal hair growth, making engraftment of human or mouse cancer cells, and tumor regression following treatment, easily observable
- Athymic: lack T cells and thus incapable of cell-mediated immunity, B cell development is partially defective
- Produces normal T cell precursors, and produces mature T cells with time
- Responses to thymus-dependent antigens (when detectable) are primarily IgM
- Challenging breeder: begins to ovulate late (at two and a half months) and stops early (at about four months), but breeds better than Foxn1nu/nu mutants on other inbred genetic backgrounds